Osteosarcoma

Human medicines European public assessment report (EPAR): Eladynos, abaloparatide, Date of authorisation: 12/12/2022, Revision: 3, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Patient, Urine, Medical Subject Headings, Marketing, INN, Risk, Fracture, Alkaline phosphatase, Woman, Allergy, Heart rate, Vitamin D, ATC, Hypercalcaemia, Menopause, International, Diet, Parathyroid hormone, Headache, Disease, Osteosarcoma, Nausea, Blood, Language, Calcium, Osteoblast, Palpitations, Cancer, Heart, Dizziness, Abdomen, European Medicines Agency, Spine, Back pain, Hypercalciuria, Select, System, Safety, Cardiovascular disease, Anatomy, Arthralgia, Bone fracture, Female, IIA, Skin, Medical device

Human medicines European public assessment report (EPAR): Eladynos, abaloparatide, Date of authorisation: 12/12/2022, Revision: 3, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Eladynos, abaloparatide, Date of authorisation: 12/12/2022, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Natpar, parathyroid hormone, Date of authorisation: 24/04/2017, Revision: 17, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Patient, Gland, Medical Subject Headings, Diarrhea, Urine, Marketing, European Commission, Agency, INN, Risk, Vitamin D, ATC, System, International, European, Headache, Disease, Needle, Osteosarcoma, Hypoesthesia, Blood, Language, Calcium, Heart, Cancer, Pseudohypoparathyroidism, European Medicines Agency, Thigh, Select, Safety, Kidney, Anatomy, Medicine, Paresthesia, Vomiting, IIA, Neck, Skin, Medical device

Human medicines European public assessment report (EPAR): Natpar, parathyroid hormone, Date of authorisation: 24/04/2017, Revision: 17, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Natpar, parathyroid hormone, Date of authorisation: 24/04/2017, Revision: 17, Status: Authorised

Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences

Retrieved on: 
Thursday, November 9, 2023
Cisplatin, Literacy, Food and Drug Administration, Neuroblastoma, FENC, Safety, COG, Food, GMT, Ototoxicity, Incidence, Risk, Patient, Medulloblastoma, FDA, Hepatoblastoma, Conference, Kool-Aid, Germ cell tumor, Survival, Hearing loss, RESEARCH, Osteosarcoma, TSX, Pharmaceutical industry

RESEARCH TRIANGLE PARK, N.C., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will be participating in upcoming conferences.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will be participating in upcoming conferences.
  • The management team will also host one-on-one investor meetings at the conferences.
  • Event: Jefferies London Healthcare Conference in London, UK
    Time: Company Presentation at 5:00 a.m.
  • It is a unique formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients.

Sarcoma Oncology Center Leverages BostonGene’s AI-Driven Molecular and Immune Profiling Platform to Identify Novel Treatment Options for Patients with Advanced Cancers

Retrieved on: 
Tuesday, December 12, 2023
Biotechnology, Technology, Health, General Health, Pharmaceutical, Oncology, Health Technology, Software, Artificial Intelligence, Genetics, Clinical Trials, Pancreatic cancer, Breast, Sarcoma, CCNG1, Breast cancer, Patient, FDA, Pancreas, Neoplasm, Cancer, Partnership, Connective tissue, Osteosarcoma, Medical imaging, Research, MD

BostonGene , a leading AI-based molecular and immune profiling solutions provider, and the Sarcoma Oncology Center , announced a collaboration to expedite the availability of DeltaRex-G.

Key Points: 
  • BostonGene , a leading AI-based molecular and immune profiling solutions provider, and the Sarcoma Oncology Center , announced a collaboration to expedite the availability of DeltaRex-G.
  • Sarcoma Oncology Center, located in Santa Monica, California, is a cancer treatment and clinical research center, recognized for its clinical trials and clinical expertise in treating patients with sarcoma.
  • Sarcoma Oncology Center partnered with BostonGene for its innovative computational platform, which leverages AI-based molecular and immune profiling.
  • “We are pleased to be working with the Sarcoma Oncology Center to support their efforts in personalizing treatments for their patients.

Teva Announces Approval of a Generic Version of Forteo® (teriparatide injection), in the U.S.

Retrieved on: 
Friday, November 17, 2023
FDA, Pharmaceutical, Health, Medicine, Vomiting, Digoxin, Osteoporosis, Woman, Urine, Antares, NYSE, Bone disease, Calcium, Spine, Prednisone, Constipation, Allergy, History, IQVIA, Patient, Arthralgia, Medication, TEVA, Fracture, Muscle weakness, System, Blood, Tongue, Vitamin, Bone tumor, Nausea, Kidney, Pain, Swelling, Osteosarcoma, Skin, Rat, TASE, Injection, Face, Blood pressure, Generic drug, Dietary supplement, Pharmaceutical industry, Vaccine, Birth control, Injection moulding, Medical imaging, Poultry farming, Phosphorus, Teriparatide, Teva

Teva Pharmaceuticals Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the approval of a generic version of Forteo®1, in the United States.

Key Points: 
  • Teva Pharmaceuticals Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the approval of a generic version of Forteo®1, in the United States.
  • Currently, 1 in 12 generic prescriptions dispensed in the U.S. is filled with a Teva generic product.
  • Teva’s generic equivalent of Forteo® (teriparatide injection) utilizes the Antares Pharma, Inc. multi-dose pen device.
  • Teriparatide injection can lessen the chance of broken bones (fractures) in the spine and other bones in postmenopausal women with osteoporosis.

Children's Hospital of Philadelphia Receives Multi-Million Dollar Gift from Holveck Family to Support Groundbreaking Osteosarcoma Research

Retrieved on: 
Thursday, November 16, 2023
Jack Holveck, Connor Boyle, Research, Radiation, Cancer, Therapy, Tissue, Hospital, Patient, Division, Science, Central Bucks School District, Neoplasm, Child, Villanova University, MD, Osteosarcoma, Grandparent, Death, Children's Hospital of Philadelphia, Family, Mitochondrion, Life, CHOP, MC2, Medical imaging, Nursing, Pharmaceutical industry

PHILADELPHIA, Nov. 16, 2023 /PRNewswire/ -- Children's Hospital of Philadelphia (CHOP) has received a $6.4 million gift from the family of Connor Boyle, a Central Bucks East High School graduate who died at age 18 from osteosarcoma.

Key Points: 
  • PHILADELPHIA, Nov. 16, 2023 /PRNewswire/ -- Children's Hospital of Philadelphia (CHOP) has received a $6.4 million gift from the family of Connor Boyle, a Central Bucks East High School graduate who died at age 18 from osteosarcoma.
  • This three-year gift, named The Connor Initiative: Precision Therapeutics for Osteosarcoma & Rare Cancers, will support cutting-edge research in osteosarcoma and other rare cancers.
  • Osteosarcoma , the most common malignant bone tumor in children and young adults, affects approximately 400 children every year in the United States.
  • "This gift to establish The Connor Initiative will provide the tools and resources to meet the challenges of treating osteosarcoma like never before."

Joel Madden Joins MIB Agents As Brand Ambassador

Retrieved on: 
Wednesday, November 15, 2023
MIB, Research, Disease, Patient, Health, Child, Osteosarcoma, Cancer, Happiness, Family, Parent, Good

BARNARD, Vt., Nov. 15, 2023 /PRNewswire/ -- Joel Madden, American singer and lead vocalist of Good Charlotte, has officially joined MIB Agents, a leading pediatric osteosarcoma nonprofit dedicated to making it better for its community of patients, families, doctors and researchers, as a Brand Ambassador.

Key Points: 
  • Last year, Joel won $200,000 on Celebrity Wheel of Fortune and donated all of his earnings to MIB Agents.
  • In his role as MIB Agents brand ambassador, Joel will raise awareness about MIB Agents' various fundraisers, programs, and community of families with his large audience to help move research forward for osteosarcoma.
  • "We are honored to have Joel Madden join the MIB Agents team to help raise awareness of the work our nonprofit organization is doing to make it better for our community of patients and families," said Ann Graham, Founder and Executive Director of MIB Agents.
  • To listen to Joel Madden's MIB Agents podcast episode, please click here .

Lirum Therapeutics Presents Positive Data on LX-101, a Novel Clinical-Stage Targeted Therapy, Demonstrating Potent Preclinical Activity Against Pediatric Sarcomas

Retrieved on: 
Tuesday, October 31, 2023
Osteosarcoma, Graves' ophthalmopathy, Alveolar rhabdomyosarcoma, Poster, TED, Sarcoma, Cancer, Therapy, Rhabdomyosarcoma, Pharmaceutical industry

LX-101, a novel clinical-stage payload-bearing targeted therapy directed to the insulin-like growth factor 1 receptor (IGF-1R), demonstrated potent anti-tumor activity against cell lines with well-established IGF-1R pathway involvement, including pediatric sarcomas.

Key Points: 
  • LX-101, a novel clinical-stage payload-bearing targeted therapy directed to the insulin-like growth factor 1 receptor (IGF-1R), demonstrated potent anti-tumor activity against cell lines with well-established IGF-1R pathway involvement, including pediatric sarcomas.
  • These include cancers with known genetic alterations affecting the IGF-1R pathway and/or with high IGF-1R expression such as Ewing’s and related sarcomas, rhabdomyosarcoma, and osteosarcoma.
  • Given these promising results, and the existing clinical data, Lirum is planning new clinical trials with LX-101 in pediatric and adult oncologic indications that carry strong ties to the IGF-1/IGF-1R pathway.
  • In parallel, Lirum is also planning to develop LX-101 in certain autoimmune diseases, such as thyroid eye disease (TED), where IGF-1R has been clinically and commercially validated.

MIB Agents Now Accepting Applications for Annual OutSmarting Osteosarcoma Research Grants

Retrieved on: 
Thursday, October 26, 2023
Osteosarcoma, MIB, Research, Scientific programming, Collaboration, Noya Fields Family Funds, Patient, Nursing, Pharmaceutical industry, Family

BARNARD, Vt., Oct. 26, 2023 /PRNewswire/ -- MIB Agents, a leading pediatric osteosarcoma nonprofit dedicated to Making It Better for its community of patients, families, medical professionals, researchers, and industry partners, is accepting applications for its annual OutSmarting Osteosarcoma research grant program. This program was established in 2017 and is awarded to projects focused on moving research forward for osteosarcoma patients. Osteosarcoma is an aggressive, malignant primary bone cancer affecting an estimated 1,000 people in the U.S. each year, about half of which are children and teens.

Key Points: 
  • BARNARD, Vt., Oct. 26, 2023 /PRNewswire/ -- MIB Agents , a leading pediatric osteosarcoma nonprofit dedicated to Making It Better for its community of patients, families, medical professionals, researchers, and industry partners, is accepting applications for its annual OutSmarting Osteosarcoma research grant program .
  • Over the past seven years, MIB Agents has awarded a total of $1,550,000 and supported 18 investigators to fund promising osteosarcoma research.
  • MIB Agents OutSmarting Osteosarcoma grants are supported by MIB Agents Family Funds, osteosarcoma patients and families who raise funds in honor of an OsteoWarrior, a patient currently battling osteosarcoma or an OsteoAngel, a loved one who has passed.
  • Collaboration among the scientific and patient community is a key hallmark of MIB Agents that makes the OutSmarting Osteosarcoma grant process unique.

OS Therapies Announces Full Enrollment in PhIIb Clinical Trial AOST-2121 in Recurred, Resected Osteosarcoma with OST-HER2 (Listeria monocytogenes) for Delay or Prevention of Recurrence

Retrieved on: 
Tuesday, September 26, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Fast, Clinical trial, OS, Cancer, AYA, RDD, COG, BTD, Prognosis, Rated R, HIV disease progression rates, USDA, Patient, Physician, Principle, OST, Recurrence, Metastasis, Disease, Pharmaceutical industry, Osteosarcoma, MD

OS Therapies, a research and clinical stage biopharmaceutical company, is extremely excited to announce Full Enrollment for its lead OST-HER2 (OST31-164) program in its ongoing clinical trial AOST-2121 (NCT04974008).

Key Points: 
  • OS Therapies, a research and clinical stage biopharmaceutical company, is extremely excited to announce Full Enrollment for its lead OST-HER2 (OST31-164) program in its ongoing clinical trial AOST-2121 (NCT04974008).
  • “Several patients have completed the treatment phase of the trial and many more are undergoing treatment with OST-HER2.
  • OS Therapies has two platform technologies: OST-HER2 and OST-TDC being developed for therapies to treat Osteosarcoma (OS) and other solid tumors including ovarian.
  • AOST-2121 is a Phase IIB clinical trial intended to prevent or delay metastasis and improve Overall Survival (OS) in Osteosarcoma.